



Trans-Pacific Aseptic Institute of Training® (TPA-IT)

China's only sterile university dedicated to training the aseptic workforce.

Aseptic fill-and-finish manufacturing is the most technically challenging of all pharmaceutical manufacturing processes, requiring people trained to execute to exacting standards in a sterile environment.

PaizaBio and partner Ausia BioTech ensure an exceptionally trained aseptic manufacturing workforce via TPA-IT, the Trans-Pacific Aseptic Institute of Training®. Located on the campus of Ausia BioTech in Hangzhou, China, the \$8 million dollar sterile university was originally established for Ausia BioTech employees. As TPA-IT, the curriculum has been expanded; it is now open to employees of other pharmaceutical companies, contract manufacturing organizations, and government and regulatory entities from around the world.

This comprehensive, full-scale training center ensures a workforce capable of the highest level of cGMP quality manufacture. Training includes structured lecture and hands-on learning experiences in the principles of sterile manufacturing, quality management and regulatory compliance. The interactive curriculum is taught by Complya

Asia in facilities that include qualified clean rooms with fully functional HVAC systems and commercial grade equipment, and a lecture hall that accommodates 50 students. The experience is designed to accelerate learning and maximize students' retention of information and skills.

Core Areas of Training

- » Theory and principles of aseptic processing
- » Pharmaceutical engineering
- » Sterile manufacturing
- » Quality management
- » Regulatory compliance
- » Operator behavior
- » Train the trainer

Our goal is to provide the highest quality training anywhere in the world to ensure students possess the knowledge and confidence required in the demanding environment of aseptic processing for the manufacture of sterile pharmaceutical products.



PaizaBio and Ausia BioTech created the Trans-Pacific Aseptic Institute of Training® to ensure an exceptional workforce for global aseptic fill-and-finish operations. All training takes place in a full-scale, dedicated facility in Hangzhou, China, using a comprehensive, industry-leading curriculum.



PaizaBio's Trans-Pacific Aseptic Institute of Training® is the source of introductory and advanced aseptic manufacturing training for those in the pharmaceutical industry. Courses are offered throughout the year. Learn more at www.PaizaBio.com.



Visit PaizaBio in China



PaizaBio's manufacturing operations are located in Hangzhou, one of China's top ten travel destinations and one of the seven ancient capitals. Hangzhou was among Marco Polo's favorite destinations due to its beauty and thriving economy, qualities that exist today. Hangzhou is less than two hours from Shanghai. We encourage you to visit PaizaBio in Hangzhou, tour our manufacturing operations, meet our people, and enjoy our home city in China.

90% of Pharmaceutical Companies Count China as a Top Priority for Growth

Multinational pharmaceutical companies can no longer afford a business as usual approach to Asia. Strategic alliances with companies with a longstanding local presence in China, particularly in the contract manufacturing arena, serve to minimize risk and advance the opportunity to quickly gain a position of strength in tune with local protocol and market conditions.

PaizaBio puts you ahead of the curve with our 20-year reputation and experience as a premier aseptic fill-and-finish and lyophilization CMO in China and decades of manufacturing and market development experience with Western drug companies.

Manufacturing in China with PaizaBio Offers

- » Significant economies of scale, from downstream manufacturing through upstream commercialization
- » Strong Sino-influence in export to developing regional countries, thus allowing rapid market penetration in Asia
- » Optimization of in-country logistics on a consistent cost basis
- » Minimization of foreign exchange risk
- » Corporate financial hedging with a top five currency, which is not exchangeable on the open market
- » Potential to capitalize on the imminent expansion of the biosimilars market in a country which is a late adopter of biological/large molecule products

PaizaBio is the proven contract manufacturing portal for sterile injectables in China, for the Chinese market, to Western standards.

Let's talk.

